(Q39601072)

English

Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents

scientific article published on December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 September 2017

Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents (English)

1 reference

Europe PubMed Central

13 September 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jean-Michel Pawlotsky

5

object named as

Jean-Michel Pawlotsky

0 references

Heiner Wedemeyer

1

object named as

Heiner Wedemeyer

1 reference

Europe PubMed Central

13 September 2017

author name string

Donald M Jensen

2

1 reference

Europe PubMed Central

13 September 2017

Eliot Godofsky

3

1 reference

Europe PubMed Central

13 September 2017

Nina Mani

4

1 reference

Europe PubMed Central

13 September 2017

Veronica Miller

6

1 reference

Europe PubMed Central

13 September 2017

Definitions/Nomenclature Working Group* of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research

7

1 reference

Europe PubMed Central

13 September 2017

language of work or name

0 references

publication date

1 December 2012

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

56

1 reference

Europe PubMed Central

13 September 2017

2398-2403

1 reference

Europe PubMed Central

13 September 2017

6

1 reference

Europe PubMed Central

13 September 2017

Directly acting antivirals against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25888

21 January 2018

Identifiers

10.1002/HEP.25888

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39601072&oldid=1844175071"